Poli Daniela, Antonucci Emilia, Pengo Vittorio, Testa Sophie, Palareti Gualtiero
Thrombosis Centre, Oncology Department, AziendaOspedaliero-Universitaria Careggi, Florence, Italy.
Start Register Section, Arianna Anticoagulazione Foundation, Bologna, Italy.
Am J Cardiol. 2017 Apr 1;119(7):1012-1016. doi: 10.1016/j.amjcard.2016.12.007. Epub 2017 Jan 26.
Anticoagulation is recommended in patients with atrial fibrillation (AF) for stroke prevention, and the bleeding risk associated suggests the need for a bleeding risk stratification. HAS-BLED (hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly >65 years, drugs/alcohol concomitantly) score includes "labile INR" referred to quality of anticoagulation. However, in naïve patients, this item is not available. In addition, stroke and bleeding risk prediction scores shared several risk factors. The aims of our study were as follows: (1) to evaluate if the HAS-BLED score in its refined form excluding "labile INR" (HAS-BED [hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, elderly, drugs/alcohol]) is still associated with bleeding risk and (2) to evaluate the predictive ability for bleeding of both stroke and bleeding prediction models. We followed an inception cohort of 4,579 patients with AF enrolled in the Survey on anticoagulaTed pAtients RegisTer (NCT02219984). Major bleeds were recorded. During follow-up (7,014 patient-years), 115 patients experienced a major bleeding (MB; rate 1.6 × 100 patient-years). Patients at high risk were better identified by HAS-BLED and HAS-BED scores with respect to CHADS (congestive heart failure, hypertension, age >75 years, diabetes, previous stroke or transient ischemic attack) and CHADSVASc (congestive heart, failure, hypertension, age [>75 years], diabetes, stroke/transient ischemic attack, vascular disease, age [65 to 74 years], female gender). HAS-BLED has a slightly higher c value in comparison to CHADS and CHADSVASc. However, among naïve patients, the predictive ability for hemorrhage of HAS-BED score is overlapping with CHADS and CHADSVASc. In low stroke risk patients (CHADSVASc = 0 to 1), only 6 patients are at high bleeding risk, and none of them experienced MB. In conclusion, in our prospective cohort of patients with AF, we found that HAS-BLED and HAS-BED scores identify patients at high bleeding risk. However, the predictive value for MB of HAS-BED used in naïve patients is similar to CHADS or CHADSVASc, suggesting that stroke stratification scores could be sufficient for tailoring treatment.
对于房颤(AF)患者,推荐进行抗凝治疗以预防卒中,而与之相关的出血风险提示需要进行出血风险分层。HAS - BLED(高血压、肝肾功能异常、卒中、出血史或倾向、国际标准化比值(INR)不稳定、年龄>65岁、同时使用药物/酒精)评分中的“INR不稳定”涉及抗凝质量。然而,对于初治患者,该项目不可用。此外,卒中和出血风险预测评分有几个共同的危险因素。我们研究的目的如下:(1)评估排除“INR不稳定”的改良版HAS - BLED评分(HAS - BED [高血压、肝肾功能异常、卒中、出血史或倾向、老年、药物/酒精])是否仍与出血风险相关,以及(2)评估卒中和出血预测模型对出血的预测能力。我们追踪了纳入抗凝患者登记调查(NCT02219984)的4579例房颤初治患者队列。记录严重出血情况。在随访期间(7014患者年),115例患者发生了严重出血(MB;发生率1.6×100患者年)。相对于CHADS(充血性心力衰竭、高血压、年龄>75岁、糖尿病、既往卒中或短暂性脑缺血发作)和CHADSVASc(充血性心力衰竭、高血压、年龄[>75岁]、糖尿病、卒中/短暂性脑缺血发作、血管疾病、年龄[65至74岁]、女性),HAS - BLED和HAS - BED评分能更好地识别高危患者。与CHADS和CHADSVASc相比,HAS - BLED的c值略高。然而,在初治患者中,HAS - BED评分对出血的预测能力与CHADS和CHADSVASc重叠。在低卒中风险患者(CHADSVASc = 0至1)中,只有6例患者处于高出血风险,且无一例发生MB。总之,在我们的房颤前瞻性队列患者中,我们发现HAS - BLED和HAS - BED评分能识别高出血风险患者。然而,初治患者中使用的HAS - BED对MB的预测价值与CHADS或CHADSVASc相似,这表明卒中分层评分可能足以指导治疗。